40 million people live with HIV globally, and that number continues to rise. While therapies exist to reduce the amount of HIV in a patient's body and, in turn, reduce HIV symptoms, there remains no ...

A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated next-generation viral vectors with significantly enhanced specificity and efficiency ...

U.K. scientists have used mass spectrometry to look in detail at how adeno-associated viruses (AAVs) release their genetic cargo when infecting host cells. The team, from the University of Leeds, ...

Scientists from Japan have developed a new technique for assessing whether adeno-associated virus (AAV) capsids are full or empty of their therapeutic DNA payload. The team hopes the research will ...

Researchers develop a large dodecahedral structure through the self- assembly of metal ions and peptides, with potential implications in drug delivery systems and molecular transportation. Controlling ...

Under a new licensing deal announced July 8, JCR Pharmaceuticals Co. Ltd. granted Alexion Pharmaceuticals Inc. rights to its adeno-associated virus (AAV) capsids for use in up to five of Alexion’s ...

- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data ...